Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 6/2017

11.05.2017

Heart failure with preserved ejection fraction: a nephrologist-directed primer

verfasst von: Baris Afsar, Patrick Rossignol, Loek van Heerebeek, Walter J. Paulus, Kevin Damman, Stephane Heymans, Vanessa van Empel, Alan Sag, Alan Maisel, Mehmet Kanbay

Erschienen in: Heart Failure Reviews | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

There is substantial causal and consequential interaction between the ever-growing heart failure and renal failure patients. Half of the patients with heart failure (HF) have preserved left ventricular ejection fraction (HFpEF), which is difficult to diagnose and rising in prevalence relative to HF with reduced EF (HFpEF). To date, only weight reduction, exercise training, and diuretics have been shown to improve exercise tolerance and morbidity in HFpEF. This review aims to establish the baseline kidney-related concepts specific to the diagnosis and treatment of HFpEF patients and the different aspects of HFpEF and HFpEF in the clinical setting.
Literatur
1.
Smith DH, Thorp ML, Gurwitz JH et al (2013) Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes 6:333–342CrossRefPubMedPubMedCentral
2.
Lloyd-Jones DM, Larson MG, Leip EP et al (2002) Lifetime risk for developing congestive heart failure the Framingham Heart Study. Circulation 106:3068–3072CrossRefPubMed
3.
Colombo PC, Ganda A, Lin J et al (2012) Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17:177–190CrossRefPubMed
4.
Go AS, Yang J, Ackerson LM et al (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure the anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation 113:2713–2723CrossRefPubMed
5.
von Haehling S, Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle 1:1–5CrossRef
6.
Curtis BM, Parfrey PS (2005) Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiol Clin 23:275–284CrossRefPubMed
7.
Bruch C, Rothenburger M, Gotzmann M et al (2007) Chronic kidney disease in patients with chronic heart failure—impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol 118:375–380CrossRefPubMed
8.
Hillege HL, Girbes AR, de Kam PJ et al (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203–210CrossRefPubMed
9.
Ather S, Chan W, Bozkurt B et al (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998–1005CrossRefPubMedPubMedCentral
10.
Lam CS, Donal E, Kraigher-Krainer E, Vasan RS (2011) Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 13:18–28CrossRefPubMed
11.
Brouwers FP, de Boer RA, van der Harst P et al (2013) Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34:1424–1431
12.
Athyros VG, Pagourelias ED, Gossios TD, Vasilikos VG (2015) Treating heart failure with preserved ejection fraction related to arterial stiffness. Can we kill two birds with one stone? Curr Vasc Pharmacol 13:368–380CrossRefPubMed
13.
Ferreira JP, Girerd N, Duarte K et al (2017) Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction: an analysis from the high-risk myocardial infarction database initiative. Circ Heart Fail 10. doi:10.​1161/​CIRCHEARTFAILURE​.​116.​003500
14.
van Riet EE, Hoes AW, Limburg A, Landman MA, Zuithoff PN, Rutten FH (2016) Effect of training general practitioners in drug treatment of newly detected heart failure patients with reduced or preserved ejection fraction: a cluster randomized trial. Int J Cardiol 217:174–182CrossRefPubMed
15.
Kao DP, Lewsey JD, Anand IS et al (2015) Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 17:925–935CrossRefPubMedPubMedCentral
16.
Unger ED, Dubin RF, Deo R et al (2015) Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 18:103–112
17.
Maaten JM, Damman K, Verhaar MC et al (2016) Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18:588–98
18.
Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA (2012) The role of the kidney in heart failure. Eur Heart J 33:2135–2142CrossRefPubMed
19.
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76–84CrossRefPubMed
20.
Sharma K, Hill T, Grams M et al (2015) Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction. Am J Cardiol 116:1534–1540CrossRefPubMed
21.
Gori M, Senni M, Gupta DK et al (2014) Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 35:3442–3451CrossRefPubMedPubMedCentral
22.
Casado J, Montero M, Formiga F et al (2013) Clinical characteristics and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. Eur J Int Med 24:677–683CrossRef
23.
Damman K, Valente MA, Voors AA, O'Connor CM, Van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469CrossRefPubMed
24.
Kawaguchi M, Hay I, Fetics B, Kass DA (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction implications for systolic and diastolic reserve limitations. Circulation 107:714–720CrossRefPubMed
25.
Bhatia RS, Tu JV, Lee DS et al (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269CrossRefPubMed
26.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259CrossRefPubMed
27.
Anand IS (2008) Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev 13:379–386CrossRefPubMed
28.
Galle J, Quaschning T, Seibold S, Wanner C (2003) Endothelial dysfunction and inflammation: what is the link? Kidney Int 63:S45–S49CrossRef
29.
Murdoch CE, Chaubey S, Zeng L et al (2014) Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 63:2734–2741CrossRefPubMed
30.
Di Marco GS, Hausberg M, Hillebrand U et al (2008) Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol-Renal Physiol 294:F1381–F1387CrossRefPubMed
31.
Stas S, Whaley-Connell A, Habibi J et al (2007) Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 148:3773–3780CrossRefPubMed
32.
Silswal N, Touchberry CD, Daniel DR et al (2014) FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol-Endocrinol Metab 307:E426–E436CrossRefPubMedPubMedCentral
33.
Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D (2012) Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis 220:265–268CrossRefPubMed
34.
Jie KE, Zaikova MA, Bergevoet MW et al (2010) Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dialysis Transplant 25:1875–1882CrossRef
35.
Yilmaz MI, Sonmez A, Saglam M et al (2008) ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 19:388–395CrossRefPubMedPubMedCentral
36.
Lam CS, Brutsaert DL (2012) Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol 60:1787–1789CrossRefPubMed
37.
Akiyama E, Sugiyama S, Matsuzawa Y et al (2012) Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 60:1778–1786CrossRefPubMed
38.
van Heerebeek L, Hamdani N, Falcão-Pires I et al (2012) Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation:CIRCULATIONAHA. 111.076075.
39.
Glezeva N, Baugh J (2014) Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev 19:681–694CrossRefPubMed
40.
Kalogeropoulos A, Georgiopoulou V, Psaty BM et al (2010) Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 55:2129–2137CrossRefPubMedPubMedCentral
41.
Moradi H, Sica DA, Kalantar-Zadeh K (2013) Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 38:136–148CrossRefPubMed
42.
Tumur Z, Niwa T (2009) Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 29:551–557CrossRefPubMed
43.
Yamamoto H, Tsuruoka S, Ioka T et al (2006) Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 69:1780–1785CrossRefPubMed
44.
Oberleithner H, Riethmüller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M (2007) Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci 104:16281–16286CrossRefPubMedPubMedCentral
45.
Miller WL, Mullan BP (2016) Volume overload profiles in patients with preserved (HFpEF) and reduced (HFrEF) ejection fraction chronic heart failure: are there differences? A pilot study. JACC: Heart Failure.
46.
Hartog JW, Smit AJ, van Son WJ et al (2004) Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 43:966–975CrossRefPubMed
47.
Stenvinkel P, Alvestrand A (2002) Review articles: inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15:329–337
48.
Smit AJ, Lutgers H (2004) The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11:2767–2784CrossRefPubMed
49.
Petrova R, Yamamoto Y, Muraki K et al (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34:1425–1431CrossRefPubMed
50.
Hartog JW, Voors AA, Bakker SJ, Smit AJ, Veldhuisen DJ (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 9:1146–1155CrossRefPubMed
51.
Zyatenkova E, Drapkina O, Ivashkin V (2014) Characteristics of vessels wall, myocardium and epicardial fat in patients with heart failure with preserved ejection fraction with and without metabolic syndrome. Endosc Ultrasound 3:S1CrossRefPubMedPubMedCentral
52.
Karakurt O, Oztekin S, Yazıhan N, Akdemir R (2011) Impaired right ventricular functions in metabolic syndrome patients with preserved left ventricular ejection fraction. Turk Kardiyol Dern Ars 39:549–556CrossRefPubMed
53.
Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263–271CrossRefPubMed
54.
Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T (2008) Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 10:1115–1126CrossRefPubMed
55.
Kamo T, Akazawa H, Komuro I (2015) Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circ Res 117:89–98CrossRefPubMed
56.
Kajimoto K, Sato N, Takano T, registry iotADHFS (2015) Association of anemia and renal dysfunction with in-hospital mortality among patients hospitalized for acute heart failure syndromes with preserved or reduced ejection fraction. Eur Heart J:2048872615593387.
57.
Rusinaru D, Buiciuc O, Houpe D, Tribouilloy C (2011) Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. Int J Cardiol 147:278–282CrossRefPubMed
58.
Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M (2016) Focus on renal congestion in heart failure. Clin Kidney J 9:39–47CrossRefPubMed
59.
Takei M, Kohsaka S, Shiraishi Y et al (2015) Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. Circ Heart Fail 8:527–532CrossRefPubMed
60.
Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122:265–272CrossRefPubMedPubMedCentral
61.
Abramov D, Cohen RS, Katz SD, Mancini D, Maurer MS (2008) Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions. Am J Cardiol 102:1069–1072CrossRefPubMedPubMedCentral
62.
Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59:442–451CrossRefPubMed
63.
Bhuiyan T, Maurer MS (2011) Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep 5:440–449CrossRefPubMedPubMedCentral
64.
Bench T, Burkhoff D, O’Connell JB et al (2009) Heart failure with normal ejection fraction: consideration of mechanisms other than diastolic dysfunction. Curr Heart Fail Rep 6:57–64CrossRefPubMed
65.
Rossignol P, Zannad F (2015) Regional differences in heart failure with preserved ejection fraction trials when nephrology meets cardiology but east does not meet west. Circulation 131:7–10CrossRefPubMed
66.
Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781CrossRefPubMed
67.
Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467CrossRefPubMed
68.
Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392CrossRefPubMed
69.
Ferreira JP, Girerd N, Rossignol P, Zannad F (2015) Geographic differences in heart failure trials. Eur J Heart Fail 17:893–905CrossRefPubMed
70.
Rossignol P, Dobre D, Gregory D et al (2014) Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. Int J Cardiol 173:380–387CrossRefPubMed
71.
Lesogor A, Cohn JN, Latini R et al (2013) Interaction between baseline and early worsening of renal function and efficacy of renin–angiotensin–aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail 15:1236–1244CrossRefPubMed
72.
Rossignol P, Dobre D, McMurray JJ et al (2013) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo additional to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail:CIRCHEARTFAILURE. 113.000792.
73.
Rossignol P, Zannad F, Pitt B (2014) Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. Int J Cardiol 177:731–733CrossRefPubMed
74.
Damman K, Perez AC, Anand IS et al (2014) Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol 64:1106–1113CrossRefPubMed
75.
McAlister FA, Ezekowitz J, Tarantini L et al (2012) Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction impact of the new chronic kidney disease-epidemiology collaboration group formula. Circ Heart Fail 5:309–314CrossRefPubMed
76.
77.
Lam CS, Roger VL, Rodeheffer RJ et al (2007) Cardiac structure and ventricular–vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115:1982–1990CrossRefPubMedPubMedCentral
78.
Ennezat PV, Maréchaux S, Six-Carpentier M et al (2011) Renal resistance index and its prognostic significance in patients with heart failure with preserved ejection fraction. Nephrol Dial Transplant 26:3908–3913CrossRefPubMed
79.
Costanzo MR, Guglin ME, Saltzberg MT et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683CrossRefPubMed
80.
Jefferies JL, Bartone C, Menon S, Egnaczyk GF, O’Brien TM, Chung ES (2013) Ultrafiltration in heart failure with preserved ejection fraction comparison with systolic heart failure patients. Circ Heart Fail 6:733–739CrossRefPubMed
81.
82.
Zile MR, Jhund PS, Baicu CF et al (2016) Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction data from the prospective comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction Study. Circ Heart Fail 9:e002551CrossRefPubMedPubMedCentral
83.
O’Seaghdha CM, Hwang S-J, Ho JE, Vasan RS, Levy D, Fox CS (2013) Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24:1470–1477CrossRefPubMedPubMedCentral
84.
Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128CrossRefPubMed
85.
Frenay A-RS YL, van der Velde AR et al (2015) Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol-Renal Physiol 308:F500–F509CrossRef
86.
Henderson NC, Mackinnon AC, Farnworth SL et al (2008) Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172:288–298CrossRefPubMedPubMedCentral
87.
AbouEzzeddine OF, Haines P, Stevens S et al (2015) Galectin-3 in heart failure with preserved ejection fraction: a RELAX trial substudy (phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure). JACC Heart Fail 3:245–252CrossRefPubMedPubMedCentral
88.
Lopez-Andrès N, Rossignol P, Iraqi W et al (2012) Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 14:74–81CrossRefPubMed
89.
Borlaug BA, Koepp KE, Melenovsky V (2015) Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 66:1672–1682CrossRefPubMed
90.
Connelly KA, Bowskill BB, Advani SL et al (2014) Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. Clin Invest Med 37:E172CrossRefPubMed
91.
Lin LM, Wu Y, Wu MF, Lin JX (2016) Focus on the novel cardiovascular drug LZC696: from evidence to clinical consideration. Cardiovasc Drugs Ther 30:623–633CrossRefPubMed
92.
Solomon SD, Zile M, Pieske B et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387–1395CrossRefPubMed
93.
Koller L, Kleber ME, Brandenburg VM, Goliasch G, Richter B, Sulzgruber P, Scharnagl H, Silbernagel G, Grammer TB, Delgado G, Tomaschitz A, Pilz S, Berger R, Mörtl D, Hülsmann M, Pacher R, März W, Niessner A (2015) Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail 8(6):1059–1067PubMed
Metadaten
Titel
Heart failure with preserved ejection fraction: a nephrologist-directed primer
verfasst von
Baris Afsar
Patrick Rossignol
Loek van Heerebeek
Walter J. Paulus
Kevin Damman
Stephane Heymans
Vanessa van Empel
Alan Sag
Alan Maisel
Mehmet Kanbay
Publikationsdatum
11.05.2017
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 6/2017
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-017-9619-2

Weitere Artikel der Ausgabe 6/2017

Heart Failure Reviews 6/2017 Zur Ausgabe

ReviewPaper

Pathophysiology of acute heart failure syndrome: a knowledge gap

ReviewPaper

Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies

ReviewPaper

Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis

ReviewPaper

Fetal programming as a predictor of adult health or disease: the need to reevaluate fetal heart function

ReviewPaper

A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition

ReviewPaper

The MOGE(S) classification for cardiomyopathies: current status and future outlook

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise